396 related articles for article (PubMed ID: 26678914)
1. The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis.
Hügle B; Horneff G
Expert Opin Pharmacother; 2016; 17(5):703-14. PubMed ID: 26678914
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial.
Tarkiainen M; Tynjälä P; Vähäsalo P; Kröger L; Aalto K; Lahdenne P
Pediatr Rheumatol Online J; 2019 Dec; 17(1):80. PubMed ID: 31842940
[TBL] [Abstract][Full Text] [Related]
3. The perioperative use of synthetic and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Fleury G; Mania S; Hannouche D; Gabay C
Swiss Med Wkly; 2017; 147():w14563. PubMed ID: 29231235
[TBL] [Abstract][Full Text] [Related]
4. Challenges and treatment options for rheumatoid arthritis during pregnancy.
Gerosa M; Schioppo T; Meroni PL
Expert Opin Pharmacother; 2016 Aug; 17(11):1539-47. PubMed ID: 27283340
[TBL] [Abstract][Full Text] [Related]
5. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
6. [Biologics in the treatment of juvenile idiopathic arthritis : A comparison of mono- and combination therapy with synthetic DMARDs].
Klein A
Z Rheumatol; 2019 Sep; 78(7):599-609. PubMed ID: 31087133
[TBL] [Abstract][Full Text] [Related]
7. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
8. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
McMahan R; Balfe LM; Greene L
J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
[TBL] [Abstract][Full Text] [Related]
9. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
[TBL] [Abstract][Full Text] [Related]
10. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.
O'Dell JR; Haire CE; Erikson N; Drymalski W; Palmer W; Eckhoff PJ; Garwood V; Maloley P; Klassen LW; Wees S; Klein H; Moore GF
N Engl J Med; 1996 May; 334(20):1287-91. PubMed ID: 8609945
[TBL] [Abstract][Full Text] [Related]
11. Leflunomide treatment in juvenile idiopathic arthritis.
Ayaz NA; Karadağ ŞG; Çakmak F; Çakan M; Tanatar A; Sönmez HE
Rheumatol Int; 2019 Sep; 39(9):1615-1619. PubMed ID: 31327053
[TBL] [Abstract][Full Text] [Related]
12. The use of methotrexate in children with rheumatic diseases.
Gutiérrez-Suárez R; Burgos-Vargas R
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S122-7. PubMed ID: 21044445
[TBL] [Abstract][Full Text] [Related]
13. Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis.
Huang B; Qiu T; Chen C; Zhang Y; Seid M; Lovell D; Brunner HI; Morgan EM;
RMD Open; 2020 Jan; 6(1):. PubMed ID: 32396520
[TBL] [Abstract][Full Text] [Related]
14. Medical therapy: where are we now?
Resman-Targoff BH
Am J Health Syst Pharm; 2006 Sep; 63(18 Suppl 4):S11-8. PubMed ID: 16960243
[TBL] [Abstract][Full Text] [Related]
15. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.
Tynjälä P; Vähäsalo P; Tarkiainen M; Kröger L; Aalto K; Malin M; Putto-Laurila A; Honkanen V; Lahdenne P
Ann Rheum Dis; 2011 Sep; 70(9):1605-12. PubMed ID: 21623000
[TBL] [Abstract][Full Text] [Related]
16. A longterm prospective real-life experience with leflunomide in juvenile idiopathic arthritis.
Alcântara AC; Leite CA; Leite AC; Sidrim JJ; Silva FS; Rocha FA
J Rheumatol; 2014 Feb; 41(2):338-44. PubMed ID: 24334641
[TBL] [Abstract][Full Text] [Related]
17. Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options.
Pagnini I; Bertini F; Cimaz R
Paediatr Drugs; 2016 Apr; 18(2):101-8. PubMed ID: 26939782
[TBL] [Abstract][Full Text] [Related]
18. The humanistic and economic burden of juvenile idiopathic arthritis in the era of biologic medication.
Gidman W; Meacock R; Symmons D
Curr Rheumatol Rep; 2015 May; 17(5):31. PubMed ID: 25874347
[TBL] [Abstract][Full Text] [Related]
19. Biologics in juvenile idiopathic arthritis: a narrative review.
Vanoni F; Minoia F; Malattia C
Eur J Pediatr; 2017 Sep; 176(9):1147-1153. PubMed ID: 28725955
[TBL] [Abstract][Full Text] [Related]
20. Management of Juvenile Idiopathic Arthritis: A Clinical Guide.
Blazina Š; Markelj G; Avramovič MZ; Toplak N; Avčin T
Paediatr Drugs; 2016 Dec; 18(6):397-412. PubMed ID: 27484749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
